• Fan Pass new artist signups and live channel activations continued to increase in April
• Friendable expects to release version 2 of Fan Pass during June 2021
• A signed letter of intent between Friendable and Santo Blockchains Labs and Santo Mining Corp. will help provide artists with an additional form of revenue – NFTs
• The music streaming industry is expected to reach $12.36 billion by 2025

Friendable (OTC: FDBL) announced that the final total number of new artist signups to its Fan Pass platform in April 2021 reached 946, a 65% increase over the March 2021 signups. These additional signups are one milestone in a long string of company achievements since Fan Pass was released in July 2020. Additionally, live channel activations rose by 2,250% in April, building on the foundation set by March successes, as the company tests new technological enhancements and onboarding features as part of version 2 of the Fan Pass Live Streaming platform (https://ibn.fm/2qQDQ). The upgrades being tested offer artist members near-instant gratification, which has helped propel growth across all facets of the operation. Other Fan Pass metrics also continue to see rising numbers, proving Friendable’s continued efforts to provide enhancements across other platform levels geared toward promoting overall growth. Alongside social media followers, artist testimonials, and the positive recognition of the Fan Pass brand, the company focuses on providing the necessary awareness and assistance needed by the developing artists on the platform. According to a recent statement from Friendable Inc. CEO Robert A. Rositano Jr. discussing the upcoming version 2 of the platform, the Fan Pass team “has listened, tweaked, and redesigned where needed and added features that can only accelerate our next push to the market. We are looking forward to many exciting developments on the horizon. We expect to be announcing our release of v2 sometime in June 2021,” Rositano Jr. added. Fan Pass is a free artist platform that is centrally focused on the relationship between artists and the fans that fuel them. The platform allows for artists to earn revenue on fan subscriptions, merchandise sales and any live ticket-based online performances. All the monetary earnings for the artist can be monitored from their exclusive Fan Pass artist dashboard. In addition to the traditional means of revenue, Friendable has taken steps to provide global entertainment and musical artist-driven non-fungible tokens (“NFTs”) and has already signed a letter of intent with Santo Blockchain Labs and Santo Mining Corp. (OTC: SANP) for their development. NFTs are units of data stored in a digital ledger (blockchain) certifying the uniqueness of the digital asset. NFTs can be used to represent items including, but not limited to, photos, audio, video, and other digital-based files. “This agreement with Santo should bring some serious excitement to our artists, which we believe will also add a unique and creative component to our business model, current artist offering, and revenue opportunities moving forward,” Rositano Jr. explained (https://ibn.fm/6f7n9). These advancements and new offerings are cementing Friendable’s strong position in expanding music streaming market. With the uncertainty of the COVID-19 pandemic still a deciding factor in many in-person events, streaming has filled the gap created by the virus. Even when in-person events are resumed, the music streaming market is not expected to slow anytime in the future, as many performances will most likely still be livestreamed, as well. By the end of 2021, U.S. music streaming revenue is projected to reach $8.67 billion. The figure is expected to continue growing at a CAGR of 9.27% from 2021-2025, reaching $12.36 billion by 2025. User penetration for 2021 is expected to reach 30.2% and round out the forecast period reaching 40.1% (https://ibn.fm/gSH6Q). Friendable and the Fan Pass platform are leveraging the numerous opportunities emerging from music streaming industry, offering new engagement possibilities for performing artists and the fans who follow them. For more information, visit the company’s websites at www.Friendable.com or www.FanPassLive.com. NOTE TO INVESTORS: The latest news and updates relating to FDBL are available in the company’s newsroom at http://ibn.fm/FDBL

• Smart technologies are enabling a new era of intelligent-tech customer services as up to 90 percent of the world’s population is expected to be using smart devices with smart assistant functions in the next few years
• Beijing-based AI solutions company Infobird recently closed its IPO on the NASDAQ exchange to demonstrate its widening reach in delivering intelligent B2B services
• The company has 70 IP rights developed under its cloud-native architecture and AI technologies
• Infobird’s B2B services provide a no-code development platform to help companies focus their efforts and financial outlays where they are most needed in multiple levels of customer service, marketing and management

A mere two decades after the Internet began to insinuate itself into individuals’ everyday lives and 14 years since the launch of Apple’s iPhone introduced the world to touchscreens and truly “smart phones,” the business of buying goods and services is becoming dependent on intelligent technologies and has more of a global outlook than ever.

Artificial intelligence (“AI”) solutions company Infobird (NASDAQ: IFBD), which also was established two decades ago, is demonstrating its commitment to pioneering the next stage of intelligent B2B customer services with its recent debut on The Nasdaq Capital Market, where it plans to raise funding primarily for marketing and technology research and development that widens the number of fields where innovative technologies are used (https://ibn.fm/BoHfd).

On the first day of trading last month, “Infobird Software’s stock triggered a circuit break several times and once rose to a high of 11.25 US dollars,” demonstrating the market’s interest in Infobird’s reputation as a premier provider of customer engagement solutions in China and belief in the value of intelligent and proactive of customer interaction in the customer relationship management as a whole, according to the Google translation of the company’s April 21 Chinese news release (https://ibn.fm/fRiNo).

“Infobird Software pioneered the cloud computing call center, created China’s leading intelligent customer service system, introduced the digital intelligent customer business philosophy, and built a nationwide customer operation and service system, using independent research and development. Technology and excellent products have served more than 70,000 enterprises,” CEO Yimin Wu stated in the news release. “Listing (on Nasdaq) is not the end, it is a new starting point, which means more opportunities and greater responsibilities.”

The news release adds that the new market listing will help Infobird accelerate its global deployment with the support of full-stack and full-chain service capabilities while becoming more open and inclusive to elements beyond its current operating borders.

Infobird is primarily directed toward key corporations in the finance industry but its expansion is demonstrated by its past experiences with clients from other industries as well, such as e-commerce giant Alibaba (NYSE: BABA).

Infobird has 70 independent intellectual property (“IP”) rights backing its self-developed cloud native architecture and AI technologies, serving banking, insurance, medical, retail and other industries.

The present pandemic society influencing the world’s economies has driven intelligent customer technologies higher at an energetic rate. As a recent CIO magazine commentary notes, this effect “can be seen across life, work, and society as industrial applications begin to solve our most pressing issues.”

The article notes that, according to Huawei’s Global Industry Vision (“GIV”) 2025 predictions, an estimated 97 percent of global enterprises will implement digital transformation through intelligent upgrades within the next few years, and that a “staggering” 90 percent of the world’s population will use smart devices with smart assistant functions while global smart home appliances use will grow to 20 billion aided by the integration of big data, AI, cloud computing and 5G network speeds.

“The twenty-year-old Infobird is a young man. We are not short of passion and drive. We hope to open up an unprecedented new path in the field of AI customer business, release more energy under the tide of economic globalization, and contribute to business and society,” Wu stated in the news release.

For more information, visit the company’s website at www.Infobird.com/en/index.html

NOTE TO INVESTORS: The latest news and updates relating to IFBD are available in the company’s newsroom at https://ibn.fm/IFBD

• Pac Roots Cannabis completed acquisition of Lords of Grasstown Holdings on February 19, 2021
• Acquisition will provide Pac Roots with foothold in lucrative Californian cannabis market, broaden its product portfolio
• Californian cannabis market generated total sales of $4.4 billion in 2020, more than double C$2.6bn value of the entire Canadian market last year

On February 19, 2021, Pac Roots Cannabis (CSE: PACR) (OTCQB: PACRF) (FSE: 4XM) announced the closing of a share purchase agreement with the shareholders of Lords of Grasstown Holdings Ltd., a well-established cannabis motorcycle lifestyle brand with a tremendous following within the motorcycle and legal cannabis communities (https://ibn.fm/pqdNY).  Whilst the acquisition is undoubtedly significant in terms of broadening out Pac Roots’ product portfolio, it also heralds Pac Root Cannabis’ entry into the lucrative United States legal cannabis market. The Lords of Grasstown brand was initially founded in 2013, designed to build upon the success of Lords of Gastown, a lifestyle and apparel brand originally founded in Canada’s Pacific Northwest and which subsequently expanded into California as of 2015. Created to fulfil a growing demand niche, the Lords of Grasstown brand started off by offering street wear apparel and related products, such as a Fight Club-inspired CBD soap line. The brand would later go on to partner with premium Canadian cannabis suppliers in a bid to introduce some of Canada’s highest testing medical cannabis strains within their product portfolio (https://ibn.fm/et6Ac). The state of California legalized the recreational adult use of cannabis in late 2016. Since then, the Californian cannabis market has grown at an astounding rate, with sales rising to $4.4 billion in 2020 (https://ibn.fm/3ScUa), up 57% relative to the previous year.  To put that figure into perspective, the entire Canadian legal cannabis market generated gross sales of C$2.6 billion ($2.09 billion) in 2020, less than half the figure achieved in the state of California alone (https://ibn.fm/tU0x7). Pac Roots Cannabis has thus far focused its efforts on the Canadian market, having successfully gathered an initial harvest of 105,000 pounds of biomass earlier this year, as part of its British Columbia-centered joint venture with Rock Creek Farms. At the time, PACR revealed that its harvest is being processed and sold in its entirety to the Speakeasy Cannabis Club (CSE: EASY) at a healthy profit margin (https://ibn.fm/8F2Kt). Pac Roots has subsequently sought to expand production, most recently through the acquisition of a substantial, 250-acre restriction-free plot of land in the Fraser Valley—one of the most intensely farmed and productive agricultural districts in Canada. From an early date, Pac Roots has looked to differentiate itself from competitors through the relentless pursuit of a genetics-based cultivation approach, which has enabled the Company to produce 50 super-elite strains and roughly 350 tested cultivars. That in turn has resulted in PACR maximizing its yields while simultaneously boosting profitability and minimizing labor costs. With the Company now poised to enter the highly lucrative Californian cannabis market, PACR’s focus on a high-quality product coupled with its ongoing efforts to increase supply bode favorably for its growth prospects going forward. For more information, visit the company’s website at www.PacRoots.ca. NOTE TO INVESTORS: The latest news and updates relating to PACR are available in the company’s newsroom at http://ibn.fm/PACR

• Extending the school day could be an important step toward securing a strong future
• Emaginos exclusive DLS system is built around STEM and enriched curriculum that is project based, student centered
• Emaginos’ strength is in providing personalized learning for students with different styles and needs

Research shows compelling evidence that longer school days — and even longer school years — can be beneficial for children. Emaginos Inc. has created a new educational model featuring longer school days and school years. The Emaginos Discovery Learning System (“DLS”) outlines a systemic transformation from the current teacher-centered model to a K-12 public education system focused on encouraging and supporting a student’s desire to learn. “The number-one reason for lengthening the school day is to provide teachers with more time for instruction,” reports a Walden University article (https://ibn.fm/hMqQg). “Over the last century, humans have acquired a staggering amount of knowledge and understanding. It makes sense that we now need to spend more time educating children, especially in the STEM fields, where knowledge is advancing rapidly and where job opportunities remain plentiful. If the U.S. is to stay competitive globally, we must produce an educated populace. Extending the school day could be an important step toward securing a strong future.” Other benefits of longer school days and school years include being more in tune with the modern world and creating a support system for working parents who needed help with childcare. “The 6.5-hour school day — and the long summer break most schools take — originated at a time when children had to help work family farms and ranches,” the Walden article noted. “But keeping this agrarian calendar makes little sense in the information age. If we want to move forward as a nation, we should ensure our children study in a way that complements modern lifestyles and needs.” Of course, providing teachers with more time for instruction is pointless if the instruction isn’t valuable, and that’s where Emaginos shines. In addition to the DLS system incorporating longer school days and school years, the comprehensive system is built around STEM and enriched curriculum that is project based and student centered. The text-free classrooms are focused on hands-on, engaged learning that incorporates state-of-the-art technology. “Emaginos’ strength is in providing personalized learning for students with different styles and needs,” said Dr. Keith Larick, Emaginos’ chief education officer and a national leader in the field of integrating technology into teaching (https://ibn.fm/JCBuH). “Over the past 10 years our three beta test schools have graduated over 1,200 students representing a 96% graduation rate. Emaginos provides the tools for young people to be effective in any profession.” Dedicated to transforming K-12 public schools to a model composed of integrated proven best practices, Emaginos opposes replacing public schools with charter schools or damaging public schools by draining resources through vouchers or school choice programs. Emaginos firmly believes in restoring the concept of the neighborhood schools as the center of the community. For more information, visit the company’s website at www.Emaginos.com. NOTE TO INVESTORS: The latest news and updates relating to Emaginos are available in the company’s newsroom at https://ibn.fm/Emaginos

• During Phase 1 trials, Berubicin showed 44% of patients experienced a clinical benefit of stable disease or better, one being cancer-free after 14 years, and two patients reporting significant tumor reduction (up to 80%)
• Additional research to be conducted by sublicensee partner WPD Pharmaceuticals, Inc. in Poland, including the first-ever pediatric trial
• The glioblastoma multiforme (“GBM”) treatment market is expected to reach $1.4 billion by 2027
• CNS Pharma positioning to secure a leading role in treating GBM

A potentially pivotal Phase 2 trial is on track to commence during Q2 2021 by CNS Pharmaceuticals (NASDAQ: CNSP). This trial is currently planned to include up to 243 subjects, randomized 2:1 (162 Berubicin/81 Lomustine) with an interim analysis when 50% of the subjects reach six months in the study. Berubicin is the lead drug candidate that CNS is working with to use against one of the most aggressive and deadly forms of treatment-resistant cancers that form in the brain – Glioblastoma Multiforme (“GBM”).

GBM is a non-discriminatory type of cancer that can strike any person at any time in their life. Of all primary malignant brain tumors, GBM accounts for 48% of them. Unfortunately, since first identified in the 1920s, the FDA has only ever approved four drugs and one device for GBM treatment. However, none of these FDA-approved approaches have succeeded in increasing life expectancy with GBM more than a few months (https://ibn.fm/JwIWV).

Berubicin is a synthetic 4’-O-Benzylated doxorubicin analog, topoisomerase II Inhibitor, highly cytotoxic, and highly lipophilic. As the first anthracycline to cross the blood-brain barrier, Berubicin was specifically designed to attack a variety of primary brain cancers and cancers metastatic to the brain.

Dr. Waldemar Priebe, Professor of Medicinal Chemistry at The University of Texas MD Anderson Cancer Center, is the original developer of Berubicin. The Phase 1 trial was completed by Reata Pharmaceuticals (NASDAQ: RETA) and showed promising results, with 44% of the trial patients experiencing significant improvement in clinical benefit. One patient from this trial has survived cancer-free for the last 14 years, while two others saw a reduction in tumor size of up to 80 percent.

CNS entered into an asset purchase agreement with Reata in 2017 and as a result holds a worldwide exclusive license to the Berubicin chemical compound and has acquired all the requisite data and know-how from Reata related to the Phase 1 trial.

In addition to the potentially pivotal trial commencing in the United States and expected to expand to include a global footprint, two additional trials are planned in Poland by CNS’s partner WPD Pharmaceuticals. WPD will be conducting two grant-funded studies including one Phase 2 adult GBM trial to commence in Q2 2021 and the first-ever Phase 1 pediatric trial for malignant gliomas set to commence during H2 2021.

CNS hopes to expand Berubicin studies to include other cancers, such as:

• Primary Brain Tumors

• • Relapsed high-grade gliomas with an estimated patient population size of 15,000
• Brain Metastases – Combination with Radiation Therapy
  • Small Cell Lung Cancer has an estimated patient population size of 56,500
  • Non-Small Cell Lung Cancer has an estimated patient population of 56,000
  • Metastatic Breast Cancer has an estimated patient population of 45,000
• CNS Lymphoma
  • 2nd line of defense after Methotrexate failure with a potential 1,200 patient population (there is currently no 2nd line therapy after Methotrexate)

The GBM treatment market is expected to grow from $662 million in 2017 to $1.4 billion in 2027, growing at a CAGR of 7.5% across eight major markets. The eight major markets include the U.S., Germany, Italy, France, Japan, the UK, Spain, and urban China (https://ibn.fm/8tcnS). With Berubicin’s ability to breach the BBB and the planned trials, CNS Pharmaceuticals is uniquely positioned to capitalize on this market growth and secure a leading role in the sector.

The interim Berubicin trial data on the Polish trial in adult GBM patients is expected in the first half of  2022. Multiple value-driving milestones are expected to transpire for CNS Pharmaceuticals during 2021, including growth opportunities for its other drug candidate currently in development, WP1244, a DNA-binding agent believed to be 500 times more potent than daunorubicin in inhibiting tumor cell proliferation, and potentially targeting brain cancers, pancreatic cancers, ovarian cancers, and lymphoma.

For more information, visit the company’s website at www.CNSPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP

• FingerMotion Inc.’s proprietary PigeonHole Integration System works in tandem with the three major Chinese telecom giants, providing a large potential for growth and customer reach, especially since the market is predicted to go unchanged despite the uncertainty of economic conditions brought on by the pandemic
• China Mobile is looking at potential A-share listings, whereas China Telecom has already announced the intention of listing with the Shanghai Stock Exchange with the issuance of 12 billion shares, with profits set to help fund the 5G industrial Internet project
• Using the data collected from these telecom giants, FingerMotion will be able to fine-tune its current offering while developing other products

FingerMotion (OTCQX: FNGR) is a technology company, constantly evolving its core competencies in mobile payment and recharge platform solutions for mainland China. FingerMotion is positioned to capitalize on the telecom market growth and opportunities, as well as its partnership with the country’s telecommunications giants, through the company’s proprietary platform and technology. It is one of only a few companies in China with access to wholesale rechargeable minutes from China’s largest mobile phone providers that can be resold to consumers.

One of China’s top mobile providers, China Mobile, is currently looking into the possibility of an A-share listing. Another one of China’s state-owned carriers, China Telecom, has already announced plans to list on the Shanghai Stock Exchange (“SSE”). The plan proposed by China Telecom will be to issue as many as 12 billion shares on the mainland China exchange – pricing is currently unknown, but it could come at a large premium. China Telecom plans to use the listing proceeds to construct a 5G industrial Internet project, boosting its cloud network. The Shanghai listing plan is currently waiting for approval by the Chinese Securities Regulatory Commission.

FingerMotion’s telecom products and services include a universal exchange platform, which has been named “PigeonHole Integration System (‘PIS’),” offering seamless integration between telecom operators and online stores.

PIS offers consumers top-up and recharge services, data plans, mobile phones, loyalty points redemption, and subscription plans. All transactions are reliable and secure, featuring real-time reconciliation and simple integration for partners with efficient settlements.

According to Research and Markets China Telecoms Report – 2020-2025, the Chinese telecommunications industry is expected to remain steady even with the political uncertainties and uncertain economic outlooks due to the COVID-19 pandemic. The report stated that the growing mobile phone penetration and high-fixed broadband among households would fuel the growth over the next five years (https://ibn.fm/lymhT).

FingerMotion is currently working to strengthen the existing and strategic partnerships it has with the Chinese telecommunication giants. Through the partnerships, the company will gain access to comprehensive and unbiased telco data on a real-time, unimpeded basis while covering a massive population. FingerMotion will then transform and integrate with its own proprietary collection for more effective and efficient capitalization and delivery using this data.

For more information, visit the company’s website at www.FingerMotion.com.

NOTE TO INVESTORS: The latest news and updates relating to FNGR are available in the company’s newsroom https://ibn.fm/FNGR

• TAAT enters agreement for GGE to be exclusive distributor for flagship product in the United Kingdom and Ireland
• “It is an exciting development for us to have received our first purchase order for overseas shipment,” says CEO
• TAAT could realize competitive advantage based on relatively high retail cost of tobacco cigarettes in the UK and Ireland

TAAT(TM) Global Alternatives (CSE: TAAT) (OTCQB: TOBAF) (FRANKFURT: 2TP2) has entered into a letter of intent with Green Global Earth Ltd. (“GGE”). The agreement calls for GGE to be the exclusive distributor for TAAT(TM)’s flagship product in the United Kingdom and Ireland. In addition, Green Global Earth placed a €100,000 purchase order for an initial supply of TAAT’s Original, Smooth and Menthol tobacco-free, nicotine-free alternative (https://ibn.fm/zazFp). “Expansion launches in the CPG category need to be conducted passively, so as to ensure the product is optimally positioned in its new markets,” said TAAT CEO Setti Coscarella. “Although we believe TAAT is generally relevant to those out of the more than one billion tobacco users worldwide who aspire to leave nicotine behind, entering a new region is a complex task based on the nuances of each market in economic and competitive terms, as well as the general attitudes towards alternatives to products such as tobacco cigarettes. “We are pleased to have an accomplished and well-connected wholesaler such as GGE on our side,” he continued. “It is an exciting development for us to have received our first purchase order for overseas shipment as we seek to commercialize TAAT internationally for the first time.” In the announcement, TAAT noted that it could realize a competitive advantage based on the relatively high retail cost of tobacco cigarettes in the UK and Ireland. The company noted that, based on data from the World Health Organization (“WHO”), the prices of the most-sold brand of cigarettes (pack of 20) in international dollars were $13.58 in the United Kingdom and $14.95 in Ireland, compared to $6.86 in the United States. With a 14.1% tobacco use incidence rate among the United Kingdom’s legal-aged population and an incidence rate of approximately 20% among adults in Ireland, TAAT sees exciting opportunities in these markets.The cost advantage combined with the incidence rate of smokers, many whom are eagerly seeking for a nicotine-free, tobacco-free alternative, place the company — and its game-changing product — in a strong position. Based on the distribution agreement between TAAT and GGE, the TAAT smoking alternative will be available through GGE’s existing wholesale network. Targeting adult-aged smokers, the rollout of the new program will capitalize on the fact that TAAT’s Beyond Tobacco(TM) experience closely mimics every sensory element of smoking a tobacco cigarette. TAAT has captured the experience through packaging, scents, crackling sounds, a tobacco taste and even the motor habits, such as hand to mouth and flicking of ashes. The success of TAAT seems to prove that smokers aren’t just reaching for cigarettes for the nicotine; rather, many enjoy the smoking ritual and experience. TAAT offers an alternative experience without compromise. TAAT Lifestyle and Wellness has developed TAAT, a tobacco-free and nicotine-free alternative to traditional cigarettes available in Original, Smooth and Menthol varieties. TAAT’s base material is Beyond Tobacco, a proprietary blend that undergoes a patent-pending refinement technique causing its scent and taste to resemble tobacco. Under executive leadership with Big Tobacco pedigree, TAAT was launched first in the United States in Q4 2020 as the company seeks to position itself in the $814 billion global tobacco industry. For more information, visit the company’s websites at www.TryTAAT.com and www.TAATGlobal.com. NOTE TO INVESTORS: The latest news and updates relating to TOBAF are available in the company’s newsroom at https://ibn.fm/TOBAF

• First order marks a significant milestone as Veterans Affairs runs the largest integrated healthcare system in the country
• BRSF hopes the relationship will bring cutting-edge brain diagnostics to a nationwide network of veterans’ health care

Brain Scientific (OTCQB: BRSF), a commercial-stage, neurology-focused medical device and software company, has announced the start of working with the U.S. Department of Veterans Affairs – VA Medical Centers, which placed the first purchase order of NeuroCap(TM) for one of its hospitals (https://ibn.fm/p3rw0). This move represents a significant milestone because the U.S. Department of Veterans Affairs runs the country’s largest integrated healthcare system. “Our team at Brain Scientific is proud to start what it hopes will be a long-term relationship to serve patient needs at VA Medical Centers and do our part to help reduce risk factors for both patients and staff. Our disposable EEG NeuroCap diminishes the potential for cross-contamination, HAI, and exposure for staff members and patients. Sanitation is a major concern for hospitals and is even more crucial in COVID-19 times as neurodiagnostic teams are urged to find alternatives to reusable products,” said Amy Griffith, vice president of strategy and business development for Brain Scientific. NeuroCap is BRSF’s flagship product, a pre-gelled disposable EEG headset targeting the growing demand for better yet cost-efficient brain monitoring. The need for this disposable and portable device is especially pronounced in the current pandemic environment, which has seen an increasing demand for EEG testing. Since more than 80% of hospitalized COVID-19 patients present with neurological symptoms, rapid EEG testing is becoming critical. This is where Brain Scientific’s NeuroCap enters the picture. Designed for quick application (video of the NeuroCap setup is available here) while also allowing for minimal exposure to patients, NeuroCap appears to be a perfect fit for the current environment where medical professionals are facing a contagious virus. The traditional bulky EEG equipment is complicated to clean between uses and is cumbersome to apply. Even after cleaning, microscopic traces of tissue debris and bacteria may remain on reusable EEG electrodes. This is where NeuroCap makes a difference. Designed for single use, this disposable device helps ensure that the virus is not spread through equipment. The innovative headset also contributes to limiting person-to-person exposure because it is applied quickly and effortlessly, decreasing virus transmission potential between medical staff and patient. Aligned with the international system, NeuroCap features 19 channels and 22 electrodes to produce high-quality study results. Also, NeuroCap is compatible with most existing EEG amplifiers on the market. With this first VA order, Brain Scientific brings this revolutionary brain diagnostics technology to Veterans Health Care, the nation’s most extensive health-care system. Veterans Health Care provides care at 1,255 health-care facilities, including 170 VA Medical Centers and 1,074 outpatient sites that serve more than 9 million veterans (https://ibn.fm/bEdHT). Committed to developing cutting-edge technologies to revolutionize brain diagnostics, Brain Scientific appears to be on the right track to tackle some of neurology’s most pressing diagnostics challenges and narrow the widening gap of accessibility to neurological care across the country. For more information, visit the company’s website at www.BrainScientific.com/Invest-Now. NOTE TO INVESTORS: The latest news and updates relating to BRSF are available in the company’s newsroom at https://ibn.fm/BRSF

• Company committed to building presence in U.S. and Europe to advance mission of improving mental health care
• New appointments will strengthen Cybin’s development and clinical operations globally, solidify position within the industry
• New leaders bring broad experience, deep insight to their new roles

Cybin (NEO: CYBN) (OTCQB: CLXPF), a leading biotech company focused on progressing psychedelic therapeutics, recently made key senior-management changes designed to provide the company with added insight and expertise in the expansion of its development and clinical operations in the United States and Europe (https://ibn.fm/FsF0L). The appointments, which are effective immediately, call for Alexander Belser, PhD, to serve as chief clinical officer and Aaron Bartlone to serve as chief operating officer.

“We are committed to building our presence both in the United States and in Europe to advance our mission of improving mental health care through therapeutic development programs and innovative drug-delivery systems,” said Cybin CEO Doug Drysdale. “These appointments will serve to strengthen our development and clinical operations globally and solidify Cybin’s position within the industry. Alex and Aaron bring deep clinical, commercial, and regulatory expertise that will serve to broaden our management and scientific leadership teams. We look forward to their contributions as we pursue increased visibility across these additional markets.”

An accomplished biopharmaceutical executive with a proven track record across numerous therapeutic and functional areas, Bartlone brings impressive quality assurance, regulatory affairs, product development, compliance, and commercial operation experience to his new role. Prior to joining Cybin, Bartlone served as both president and managing director for AB Dynamix LLC. In those roles, he oversaw the development of customized and innovative quality-management systems, regulatory strategies, and supply chains for developing pharmaceutical, biotechnology, and medical-device companies.

Bartlone has also worked at UCB Inc., a global pharmaceutical company, and Eli Lilly. He has developed global teams of more than 1,000 colleagues in 50 different countries and has successfully driven more than 25 small and large molecular therapies and drug-device combination products to the global marketplace.

A well-known leader in the field of psychedelic research, Belser has invaluable insight and expertise as an investigator on NYU and Yale University clinical trials of psilocybin and MDMA designed to treat depression, anxiety, substance use, obsessive-compulsive disorder, post-traumatic stress disorder, and end-of-life distress. A former chief clinical officer at Adelia Therapeutics, Belser directed the clinical program investigating tryptamines and phenethylamines for a variety of treatment indications.

In addition, Belser is the founding president of Nautilus Sanctuary, the first nonprofit center for psychedelic medicine in the Eastern United States, and is a recognized expert on psychedelic medicine, having authored a dozen peer-reviewed publications and delivered more than 50 lectures, presentations, and grand rounds on psychedelic topics.

In addition, Cybin also noted that cofounder and former COO Paul Glavine will assume the role of chief growth officer and John Kanakis, cofounder and former SVP of business development, will assume the role of chief business officer.

“Paul and John’s extensive entrepreneurial experience was instrumental in shaping the initial formation of Cybin and the company’s subsequent emergence as a leader within the psychedelics space,” Drysdale stated. “Their deep commitment to Cybin’s mission will continue as they assume these new roles and will allow them to further accelerate business-development and investor-awareness initiatives. We believe these appointments are an important step in taking Cybin to the next level.”

Cybin Corp., a leading biotech company focused on progressing psychedelic therapeutics, is on a mission to revolutionize mental health care. The company is focused on progressing psychedelic therapeutics by utilizing proprietary drug-discovery platforms, innovative drug-delivery systems, novel formulation approaches, and treatment regimens for psychiatric disorders.

For more information, visit the company’s website at www.Cybin.com.

NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://ibn.fm/CYBN

• GLDFF closes on majority ownership of Fifth & Root Inc.
• The acquisition of these distribution channels “greatly increases the company’s visibility and reach,” says CEO
• Fifth & Root brand are ideal match for Golden Leaf and its commitment to produce variety of products for new users as well as seasoned customers

In another move designed to advance its Crawl, Walk, Run strategy, Golden Leaf Holdings (CSE: GLH) (OTCQB: GLDFF) has announced the closing of its previously announced majority ownership purchase of Fifth & Root Inc., a nationally recognized CBD skincare brand based in California (https://ibn.fm/iOdyV). Golden Leaf is a premier, consumer-driven cannabis company specializing in retail, production, processing, wholesale, and distribution of high-quality cannabis. “The acquisition of these distribution channels greatly increases the company’s visibility and reach, and continues to advance our Crawl, Walk, Run strategic approach,” said Golden Leaf CEO Jeff Yapp. “As we look forward to the eventual federal legalization of cannabis, Fifth & Root’s commerce platform and partnerships will position the company favorably to capitalize on the evolving marketplace. Fifth & Root, a leader in CBD beauty, offers an exceptional line of clean and innovative products. We’re thrilled to add them to Golden Leaf Holdings’ portfolio of products and look forward to growing this brand within the burgeoning CBD skin-care space.” Designed with a “GenZennial” customer in mind, the Fifth & Root brand is an ideal match for Golden Leaf and its commitment to produce a variety of products for new users as well as seasoned customers for both medical and recreational use, with a focus on optimal health and wellness. Fifth and Root was formulated and designed to capture the “vibe of the innovative and experiential formulas in both branding and packaging,” observed Leilah Mundt, founder of beauty branding and sales agency Crème Collective, which worked on the branding for the line. “The formulas are bright and alive with sophisticated terpene blends that smell incredible, as well as being a proven delivery system for the active ingredients. Our goal was to mirror this in all brand touch points.” Fifth & Root is distinctive in that it is a women-founded company; in addition, its products are created and developed by women scientists and herbalists. From the beginning, the vision was to bring transformative, spell-binding skin care to consumers. The line offers powerful, effective formulations that omit toxins and irritants, including toxic chemicals, synthetics, GMOs, parabens, phthalates, harsh preservatives, skin-stripping sulfates and animal byproducts. Fifth & Root products—there are currently six—are sold in more than 425 retail locations, including national retailers such as Ulta Beauty, Nordstrom, Urban Outfitters, Anthropologie, Revolve and more. In addition, it can be purchased online (https://ibn.fm/xuwJ0). Golden Leaf Holdings is a premier consumer-driven cannabis company specializing in production, processing, wholesale, distribution and retail, with seven dispensaries in Portland, Oregon. The company is committed to developing a dynamic portfolio built around the recognized brands of Chalice Farms, with a focus on health and wellness. Markets served include Oregon, California, Nevada, and Washington. For more information, visit the company’s website at www.GoldenLeafHoldings.com. NOTE TO INVESTORS: The latest news and updates relating to GLDFF are available in the company’s newsroom at https://ibn.fm/GLDFF